Munck J N, Dhermain F, Koscielny S, Girinsky T, Carde P, Bosq J, Decaudin D, Juliéron M, Cosset J M, Hayat M
Institut Gustave-Roussy, Villejuif, France.
Ann Oncol. 1996 Nov;7(9):925-31. doi: 10.1093/oxfordjournals.annonc.a010795.
The role and timing of radiotherapy for optimal treatment of localized aggressive non-Hodgkin's lymphoma (NHL) is controversial. We report the long-term results of a single-institution pilot study of alternating chemotherapy (CT) and radiotherapy (RT) in patients with clinical stages I or II tumors exceeding 5 cm.
From 1981 to 1992, 96 patients with stages I-II aggressive NHL received an alternating regimen of CT and RT consisting of 8 cycles of CT with 3 courses of RT interjected after the 2nd, 3rd and 4th cycles of CT. The CT combined cyclophosphamide, doxorubicin, teniposide and prednisone every 28 days. Each RT course was started 8 to 10 days after CT (15 Gy in 6 fractions to initially involved and contiguous areas).
The median age was 54 years. The disease predominantly located in the head and neck area was stage II in 63% of patients. Bulky tumors (10 cm or larger) were found in 24% of patients. Six patients discontinued CT because of acute toxicity (mucositis). The mean relative dose intensity achieved for doxorubicin, cyclophosphamide and teniposide were 72%, 82%, and 78%, respectively. Late toxicity consisted mostly of severe xerostomia lasting more than 2 years in 7 patients irradiated in Waldeyer's ring. The complete response (CR) rate was 91%; 20 of the 86 patients in CR relapsed (3 locally only). The median follow-up was 61 months, and at 5 years, overall survival (OS) was 77%. Classification according to the International Prognostic Factor Index was possible for 54 patients, all but three of whom were in the 'low risk' group (0-1 factor). Bulky disease was the only unfavorable prognostic factor (P < 0.001) for CR, freedom from progression (FFP) and OS rates; the low relative dose intensity of CT achieved in this study did not affect outcome.
Alternating chemo-radiotherapy for localized aggressive NHL was feasible and yielded long-term results comparable to those obtained with standard treatments, despite a reduction in dose intensity considerably below that of CHOP which suggested synergistic effects of CT and RT in this scheme.
对于局限性侵袭性非霍奇金淋巴瘤(NHL)的最佳治疗,放疗的作用及时机存在争议。我们报告了一项单机构试点研究的长期结果,该研究针对临床分期为I期或II期且肿瘤直径超过5 cm的患者采用化疗(CT)与放疗(RT)交替进行的治疗方案。
1981年至1992年期间,96例I-II期侵袭性NHL患者接受了CT与RT交替治疗方案,包括8个周期的CT,在CT的第2、3和4个周期后穿插3个疗程的RT。CT方案为每28天联合使用环磷酰胺、阿霉素、替尼泊苷和泼尼松。每个RT疗程在CT后8至10天开始(对初始受累及相邻区域给予6次分割共15 Gy)。
中位年龄为54岁。疾病主要位于头颈部区域的患者占63%。24%的患者存在巨大肿瘤(直径10 cm或更大)。6例患者因急性毒性(粘膜炎)停止CT治疗。阿霉素、环磷酰胺和替尼泊苷的平均相对剂量强度分别达到72%、82%和78%。晚期毒性主要表现为7例在Waldeyer环接受放疗的患者出现持续超过2年的严重口干。完全缓解(CR)率为91%;86例CR患者中有20例复发(仅3例为局部复发)。中位随访时间为61个月,5年时总生存率(OS)为77%。54例患者可根据国际预后因素指数进行分类,除3例患者外,其余均属于“低风险”组(0-1个因素)。巨大肿瘤是CR、无进展生存期(FFP)和OS率的唯一不良预后因素(P < 0.001);本研究中CT相对剂量强度较低并未影响治疗结果。
对于局限性侵袭性NHL,交替放化疗是可行的,并且产生了与标准治疗相当的长期结果,尽管剂量强度明显低于CHOP方案,但提示CT与RT在此方案中具有协同作用。